Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
47.25
+2.82 (6.35%)
Oct 19, 2026, 2:04 PM EDT - Market open
Pulse Biosciences Revenue
Pulse Biosciences had revenue of $434.00K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $1.19M. In the year 2025, Pulse Biosciences had annual revenue of $350.00K. That makes Pulse Biosciences the 43,341st largest company in the world by revenue and 6,024th in the United States.
Revenue (ttm)
$1.19M
Revenue Growth
n/a
P/S Ratio
2,806.86
Revenue / Employee
$10,216
Employees
116
Market Cap
3.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 350.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
| Dec 31, 2021 | 1.42M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bausch + Lomb | 5.32B |
| DENTSPLY SIRONA | 3.64B |
| MiniMed Group | 3.22B |
| Envista Holdings | 2.86B |
| Teleflex | 2.25B |
| ICU Medical | 2.16B |
| Merit Medical Systems | 1.58B |
| Stevanato Group | 1.40B |
PLSE News
- 5 days ago - Pulse Biosciences announces partnership with Clayman Thyroid Center - TheFly
- 5 days ago - Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center - Business Wire
- 6 days ago - Pulse Biosciences price target raised to $60 from $35 at Oppenheimer - TheFly
- 6 days ago - Pulse Biosciences price target raised to $55 from $45 at Mizuho - TheFly
- 9 days ago - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026 - Business Wire
- 12 days ago - Pulse Biosciences announces NANOPULSE-AF study met enrollment target - TheFly
- 12 days ago - Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment - Business Wire